Humana (NYSE:HUM) Rating Increased to Neutral at Bank of America

Bank of America upgraded shares of Humana (NYSE:HUM) from an underperform rating to a neutral rating in a research report report published on Wednesday, MarketBeat reports. Bank of America currently has $308.00 price target on the insurance provider’s stock, up from their previous price target of $247.00.

HUM has been the topic of a number of other reports. Jefferies Financial Group cut Humana from a “buy” rating to a “hold” rating and lowered their price target for the stock from $519.00 to $253.00 in a report on Monday, October 7th. KeyCorp began coverage on shares of Humana in a report on Friday, October 11th. They issued a “sector weight” rating on the stock. Stephens reaffirmed an “equal weight” rating and set a $250.00 target price on shares of Humana in a research note on Wednesday, October 9th. Oppenheimer decreased their price target on shares of Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research note on Thursday, October 3rd. Finally, Truist Financial cut their price objective on Humana from $400.00 to $260.00 and set a “hold” rating for the company in a research report on Friday, October 11th. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus price target of $315.86.

Humana Stock Performance

Shares of NYSE HUM opened at $288.12 on Wednesday. The stock has a market cap of $34.69 billion, a PE ratio of 25.52, a price-to-earnings-growth ratio of 2.28 and a beta of 0.52. Humana has a 1 year low of $213.31 and a 1 year high of $527.18. The firm has a fifty day moving average price of $289.38 and a 200-day moving average price of $332.67. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities analysts anticipate that Humana will post 15.83 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is currently 31.36%.

Institutional Trading of Humana

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mendota Financial Group LLC increased its holdings in shares of Humana by 9.2% in the second quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 27 shares during the period. Capital Advisors Ltd. LLC increased its holdings in Humana by 17.0% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after buying an additional 31 shares during the period. CarsonAllaria Wealth Management Ltd. raised its position in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after buying an additional 39 shares during the last quarter. Moors & Cabot Inc. lifted its stake in Humana by 2.5% during the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after acquiring an additional 40 shares during the period. Finally, Harbour Investments Inc. boosted its holdings in shares of Humana by 10.5% in the 2nd quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock valued at $161,000 after acquiring an additional 41 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.